Northstar Group Inc. Sells 413 Shares of Johnson & Johnson (NYSE:JNJ)

Northstar Group Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,053 shares of the company’s stock after selling 413 shares during the quarter. Johnson & Johnson accounts for approximately 1.1% of Northstar Group Inc.’s portfolio, making the stock its 20th largest position. Northstar Group Inc.’s holdings in Johnson & Johnson were worth $6,491,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Meridian Financial Partners LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at $1,626,000. Summit Financial Wealth Advisors LLC boosted its stake in Johnson & Johnson by 26.3% during the 1st quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock valued at $853,000 after purchasing an additional 1,122 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC increased its holdings in Johnson & Johnson by 0.7% during the 1st quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock worth $7,464,000 after purchasing an additional 325 shares in the last quarter. Capital Asset Advisory Services LLC raised its stake in shares of Johnson & Johnson by 8.8% in the first quarter. Capital Asset Advisory Services LLC now owns 26,539 shares of the company’s stock worth $4,044,000 after purchasing an additional 2,151 shares during the last quarter. Finally, NTV Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 1.6% in the first quarter. NTV Asset Management LLC now owns 36,000 shares of the company’s stock valued at $5,695,000 after purchasing an additional 565 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.69 during midday trading on Thursday, hitting $161.34. 396,395 shares of the company’s stock were exchanged, compared to its average volume of 7,026,207. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a market cap of $388.29 billion, a price-to-earnings ratio of 10.02, a PEG ratio of 2.69 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The business’s fifty day moving average price is $162.65 and its two-hundred day moving average price is $154.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.80 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 30th. TD Cowen decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Sanford C. Bernstein upped their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.43.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.